Technology IPOs adding high-growth companies to the ASX 

Max Cunningham, ASX 

ASX's EGM of Issuer Services and Investment Products explains how the outlook for the tech sector and tech listings has never looked brighter. 

ASX IPO Review 2020

James Posnett, ASX 

Looking back at ASX IPOs in 2020 and insights into trends and IPOs in the year ahead. 

Top 5 remuneration planning considerations for pre-IPO companies

Kirsten Ross CFA, Aon Advisory Australia

In this article, we start with framing the differences in approach to remuneration between the private and listed spaces and the top 5 remuneration planning considerations for pre-IPO companies.

ASX in New Zealand: 2020, the year the tyranny of distance became our “liberty of distance” 

Blair Harrison, ASX

It is of no surprise that technology company listings from New Zealand are trending upwards.

Resources and Tech lead charge for ASX IPOs 

Josh Collard, ASX

Secondary capital raisings have started to make way for IPOs as companies are dusting off deferred IPO plans to take advantage of current market conditions

Get to know ASX’s new public company: Aroa Biosurgery

Blair Harrison, ASX

Aroa Biosurgery (ASX: ARX) is ASX’s 57th New Zealand IPO and listed with a market capitalisation of $225 million

The Times They Are A Changin’: ASX Emerging as a Force for Tech and its Stakeholders

Richard Horton, Squire Patton Boggs

ASX as a truly robust fundraising and exit platform for mid-stage technology startups both locally and globally represents a remarkable achievement for the ASX in the world of tech

The changing face of capital markets 

James Lee, Jarden

Investors are facing a very simple problem; increased capital for a home in what is now a significantly more volatile and complex market.

ASX markets flare on secondary capital raisings 

Listings Business Development, ASX

As Australia has taken measures to stabilise its economy, COVID-19 has subdued global IPO activity, and ASX has been no exception. However, from March to May 2020, more than 200 listed companies have accessed ASX’s market to raise over $20 billion in secondary capital. This success has been underpinned by Australia’s highly active capital market, a robust but flexible regulatory regime, and the ability to mobilise capital quickly.

Get to know ASX's new public company - Atomo Diagnostics

Belinda Chiu, ASX

Atomo Diagnostics Limited (ASX: AT1) made its debut on the Australian Securities Exchange (ASX) on 16 April 2020, following an oversubscribed initial public offering (IPO) of $30 million at a price of $0.20 per share. John Kelly, co-founder and Managing Director discusses Atomo's unique IPO journey.

IPO preparation amidst market volatility

Gavan Carroll, Ord Minnett

Gavan Carroll, Executive Director, Corporate Finance at Ord Minnett, discusses how IPO markets are adjusting to erratic conditions and why companies can use this period to prime their business to be IPO-ready when the window re-opens.

The S&P/ASX All Technology Index and the Australian technology sector 

Cameron Gleeson, BetaShares

The S&P/ASX All Technology Index (XTX) was launched in February 2020 to provide a comprehensive benchmark of ASX-listed technology companies and to facilitate investment in the fast-growing sector. Cameron Gleeson, Senior Investment Specialist, BetaShares provides insights on the XTX, following the latest quarterly re-balance.